Squarepoint
ANIX icon

Squarepoint’s Anixa Biosciences ANIX Stock Holding History

Squarepoint’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,676
Closed -$83.2K – 4229
2025
Q4 		$83.2K Buy
+26,676
New +$109K ﹤0.01% 4065
2024
Q2 		– Sell
-15,897
Closed -$49.6K – 4021
2024
Q1 		$49.6K Buy
+15,897
New +$63.4K ﹤0.01% 3877
2023
Q4 		– Sell
-13,514
Closed -$44.2K – 3978
2023
Q3 		$44.2K Buy
+13,514
New +$47.3K ﹤0.01% 3649

Other funds holding ANIX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Squarepoint's ANIX Position: Q1 2026 in Review

Squarepoint sold out of Anixa Biosciences (ANIX) in Q1 2026, closing a stake of 26,676 shares — an estimated $83.2K sold.

Squarepoint first reported a position in ANIX in Q3 2023 and held it in 3 quarters. The position peaked at $83.2K in Q4 2025. 60 funds tracked by Wall St. Rank hold ANIX as of Q1 2026.

  • Squarepoint reported no remaining Anixa Biosciences position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 26,676 Anixa Biosciences shares in Q1 2026, an estimated $83.2K.
  • Squarepoint first reported a position in Anixa Biosciences in Q3 2023 and held it in 3 quarters.
  • Squarepoint's Anixa Biosciences position peaked at $83.2K in Q4 2025.
  • 60 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.